In December, published in Surgery, surgeons from University of California, San Diego, California provided evidence on cost effectiveness of fluorescent cholangiography versus standard bright light lap chole for non-cancerous gallbladder disease.
The model predicted that compared to standard bright light laparoscopic cholecystectomy
- Fluorescent cholangiography reduces lifetime costs by $1,235 per patient
- Fluorescent cholangiography improves effectiveness by 0.09 quality-adjusted life-years
- Reduced costs were due to a decreased operative duration (21.20 minutes, P < .0001) and rate of conversion to open (1.62% vs 6.70%, P < .0001) are associated with fluorescent cholangiography
Conclusion: “The current evidence favors routine use of fluorescent cholangiography during laparoscopic cholecystectomy as a cost-effective surgical strategy”. Their model predicts that “fluorescent cholangiography reduces costs while improving health outcomes, suggesting fluorescence imaging may be considered standard surgical management for noncancerous gallbladder disease”.